Psychiatrists have developed new clinical guidelines for treating bipolar disorder and schizophrenia.
Psychiatrists have developed new clinical guidelines for treating bipolar disorder and schizophrenia.
The guidelines, published as a supplement to the November issue of the Journal of Clinical Psychiatry, are based on surveys of approximately 150 psychiatric research specialists.
Faculty members from Duke University, Columbia University and Cornell University directed the project. Abbott Laboratories and Janssen Pharmaceutica funded the project through unrestricted educational grants.
The bipolar disorder guidelines named divalproex sodium, marketed as Depakote by Abbott Laboratories, and lithium as the first-line treatment for manic episodes. Divalproex sodium is rated the best tolerated treatment for preventing future episodes.
The guidelines also stated that combinations of carbamazepine, divalproex sodium and lithium should be used for treatment-resistant manic episodes. If these treatments fail, electroconvulsive therapy or Sandoz's antipsychotic medication Clozaril (clozapine) should be considered.
Researchers also said it is crucial for clinicians to educate patients and families about the medical nature of bipolar disorder and the need for taking medication. Clinicians should help patients and families develop coping strategies for stresses that may bring on episodes of mania and depression.
The schizophrenia guidelines named both Janssen's antipsychotic Risperdal (risperidone), and traditional antipsychotics such as haloperidol as first-line treatments for an initial episode of schizophrenia and for relapses.
The guidelines said clinicians should consider risperidone for any patient who has failed to respond to traditional antipsychotic medication.
As with bipolar disorder, it is crucial for clinicians to educate patients about the need for taking medication. Patients who have problems remaining on medications may benefit from outreach efforts with assigned caseworkers. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.